IP Group

Dukosi Ltd is a company that specializes in the design, development, and manufacture of advanced battery management systems, primarily serving the automotive industry. Founded in 2003 and located in Edinburgh, United Kingdom, Dukosi offers innovative cell sensor products tailored for hybrid, plug-in hybrid, and electric vehicles, as well as electric bicycles and mobility solutions. The company's technology enables real-time monitoring of individual battery cell health, contributing to enhanced performance and longevity. Dukosi's solutions are aimed at providing reliable and renewable energy sources for vehicles, transport networks, and various applications, thereby supporting the transition to cleaner energy technologies.

SAW DX Ltd is a technology development company based in Glasgow, United Kingdom, that specializes in designing and manufacturing point-of-care (POC) diagnostic devices. The company leverages innovative Acoustic-Flow technology, which utilizes surface acoustic waves to drive diagnostic tests by manipulating fluid movement and microstructures on disposable chips. This approach allows for on-chip sample processing without the need for preprocessing, streamlining the diagnostic process. SAW DX's product offerings include prototypes for diagnosing sexually transmitted infections, demonstrator readers and cartridges for tuberculosis assays, and platforms for enriching parasites and performing molecular detection with low-cost disposable chips. The company primarily serves life sciences and diagnostics organizations seeking to enhance their diagnostic capabilities through advanced POC solutions. Incorporated in 2013, SAW DX aims to provide faster, more efficient, and cost-effective diagnostic methods for infectious diseases.

Dukosi Ltd is a company that specializes in the design, development, and manufacture of advanced battery management systems, primarily serving the automotive industry. Founded in 2003 and located in Edinburgh, United Kingdom, Dukosi offers innovative cell sensor products tailored for hybrid, plug-in hybrid, and electric vehicles, as well as electric bicycles and mobility solutions. The company's technology enables real-time monitoring of individual battery cell health, contributing to enhanced performance and longevity. Dukosi's solutions are aimed at providing reliable and renewable energy sources for vehicles, transport networks, and various applications, thereby supporting the transition to cleaner energy technologies.

Dukosi Ltd is a company that specializes in the design, development, and manufacture of advanced battery management systems, primarily serving the automotive industry. Founded in 2003 and located in Edinburgh, United Kingdom, Dukosi offers innovative cell sensor products tailored for hybrid, plug-in hybrid, and electric vehicles, as well as electric bicycles and mobility solutions. The company's technology enables real-time monitoring of individual battery cell health, contributing to enhanced performance and longevity. Dukosi's solutions are aimed at providing reliable and renewable energy sources for vehicles, transport networks, and various applications, thereby supporting the transition to cleaner energy technologies.

Anacail Limited is a technology company based in Glasgow, United Kingdom, founded in 2010. It specializes in the development of innovative ozone-based systems for the sterilization of products within sealed packaging. Anacail's technology generates ozone directly in the final product packaging, effectively oxidizing surface contaminants and eliminating microorganisms without leaving any residual chemicals. This approach not only enhances food safety and extends shelf life but also addresses handling and safety concerns typically associated with ozone use. The company provides equipment for integration into food processing lines, as well as devices for medical sterilization, offering a safe and efficient method for achieving chemical-free sterilization of packaged goods.

Relitect Limited is a technology company based in Motherwell, United Kingdom, focused on developing innovative diagnostic solutions for the life sciences industry. Founded in 2014, Relitect specializes in a novel assay platform that enables label-free electrochemical detection of binding events. This proprietary technology allows for the highly sensitive analysis of proteins, small molecules, and nucleic acids, making it suitable for clinical diagnostics and research applications. By utilizing small sample volumes and a multiplexed format, Relitect's technology minimizes sample interference and eliminates the potential for cross-talk between labeled reagents, enhancing the accuracy of biomarker detection.

Dukosi Ltd is a company that specializes in the design, development, and manufacture of advanced battery management systems, primarily serving the automotive industry. Founded in 2003 and located in Edinburgh, United Kingdom, Dukosi offers innovative cell sensor products tailored for hybrid, plug-in hybrid, and electric vehicles, as well as electric bicycles and mobility solutions. The company's technology enables real-time monitoring of individual battery cell health, contributing to enhanced performance and longevity. Dukosi's solutions are aimed at providing reliable and renewable energy sources for vehicles, transport networks, and various applications, thereby supporting the transition to cleaner energy technologies.

Ubiquigent Limited is a biotechnology company based in Dundee, United Kingdom, founded in 2009. It specializes in the development and supply of high-quality reagents, kits, and drug discovery assay development services, focusing on the ubiquitin and ubiquitin-like signaling systems. The company provides protein degradation-focused drug discovery services and designs novel deubiquitylase (DUB) enzyme inhibitors as potential therapeutics for addressing unmet medical needs. Ubiquigent collaborates with both academic and pharmaceutical researchers, supporting fundamental scientific discovery and the exploration of innovative drug candidates targeting DUBs. Its hybrid business model emphasizes the generation of intellectual property while maintaining an internal pipeline of drug discovery programs aimed at optimizing compounds for critical therapeutic areas.

Clyde Biosciences is a developer of cardiac cell analysis solutions that provide human-relevant data to de-risk drug development. The company creates cell-based assays and analytics to reveal how drug compounds affect heart cells, enabling assessment of efficacy and potential cardiotoxicity in early research. Its offerings include cellOPTIQ, an optical action potential assay that measures drug effects on human cardiomyocytes, and XTENDSR, which quantifies drug-induced changes in cardiac sarcoplasmic reticulum function. By translating cellular responses into functional cardiomyocyte data, Clyde Biosciences supports pharmaceutical and biotechnology companies in identifying safety risks earlier and guiding molecule selection. Headquartered in Glasgow, United Kingdom, the company serves clients internationally and focuses on delivering human-relevant, mechanistic insights to improve the safety profile of new medicines.